| Literature DB >> 30028852 |
Nicole Young1,2, Miriam Taegtmeyer1, George Aol3, Godfrey M Bigogo3, Penelope A Phillips-Howard2, Jenny Hill2, Kayla F Laserson4, Feiko Ter Kuile2, Meghna Desai5.
Abstract
BACKGROUND: In sub-Saharan Africa, HIV, syphilis, <span class="Disease">malaria and anaemia are leading preventable causes of adverse pregnancy outcomes. In Kenya, policy states women should be tested for all four conditions (malaria only if febrile) at first antenatal care (ANC) visit. In practice, while HIV screening is conducted, coverage of screening for the others is suboptimal and early pregnancy management of illnesses is compromised. This is particularly evident at rural dispensaries that lack laboratories and have parallel programmes for HIV, reproductive health and malaria, resulting in fractured and inadequate care for women.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30028852 PMCID: PMC6054376 DOI: 10.1371/journal.pone.0198784
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Appropriate clinical management for positive test results and preventive care at first ANC visit [50].
| Condition | For treatment | For prevention |
|---|---|---|
| HIV | Initiate PMTCT; counsel; give cotrimoxazole and start triple therapy with antiretrovirals | |
| Syphilis | Provide single dose of 2.4 MU benzathine penicillin or if penicillin allergic and unable to access penicillin desensitization, give erythromycin 500 mg three times daily for seven days and counsel on partner notification | |
| Malaria | Uncomplicated malaria: give quinine in first trimester; give artemether/lumefantrine (AL), quinine or dihydroartemisinin-piperaquine (DP) in second or third trimester; clinical severe malaria: refer to hospital | Give directly observed IPTp-SP for malaria for women in second or third trimester not on cotrimoxazole; give ITN and advise to sleep under it. |
| Anaemia | Mild anaemia (Hb <10 g/dL): give 120 mg daily elemental iron; moderate anaemia (Hb 5–7.9 g/dL): as above and provide additional iron dextran; severe anaemia (Hb is <5 g/dL): refer to hospital | Not anaemic (Hb >10 g/dL): give 65 mg daily elemental iron |
| Neural tube defects | Low dose (0.4 mg) folic acid daily; if low dose folic acid is not available, high dose (5 mg) tablets should not be administered with SP but can be taken 14 days following administration of IPTp-SP. |
ANC: antenatal care; POCT; point-of-care testing; PMTCT: prevention of mother-to-child transmission; IPTp-SP: intermittent preventive therapy in pregnancy with sulfadoxine-pyrimethamine; ITN: insecticide-treated net
Indicators of adoption, fidelity, and proposed success endpoints [51].
| Indicators of adoption and fidelity | Indicator measure | Data source | Success endpoints | |
|---|---|---|---|---|
| Adoption | Testing uptake and synergy into HIV programme | % of pregnant women tested for syphilis, malaria and anaemia by POCTs; unchanged or improved % of women tested for HIV | ANC register | ≥ 90% tested; ≥0% change in HIV testing rates |
| Fidelity | Clinical management | % of pregnant women who receive appropriate: | Exit interviews | ≥90% received |
| Information giving | % of pregnant women who were given: | Exit interviews | ≥90% given/counselled/advised | |
| Health worker proficiency of POCT | Proficiency scores measuring the ability of the health care worker to correctly perform rapid diagnostic tests per manufacturer guidelines | Proficiency scores (%) | ≥90% on check-list | |
POCTs: point-of-care tests; POCT: point-of-care testing; ANC: antenatal care
Fig 1Proportion tested for condition pre (n = 529) and during (n = 586) integrated POCT programme by facility.
*No data on number of women tested for malaria were available from the antenatal care registers before the intervention and therefore pre- and post-proportions were not comparable; ^profile pre-integrated POCT includes HIV, syphilis and anaemia; profile during integrated POCT includes HIV, syphilis, malaria and anaemia; POCT: point-of-care testing; RD: risk difference, interpreted as the difference in testing proportions before and during integrated POCT.
Test positivity rates and demographic characteristics of women aged between 15–49 years and <28 weeks pregnant, based on data from ANC registers 8.5 months before and 8 months during integrated POCT programme.
| All | All | Not interviewed n = 106 | Interviewed n = 480 | P-value | |
| HIV | n = 529 | n = 585 | n = 105 | n = 480 | |
| known positive | 78/529 (14.7%) | 77/585 (13.2%) | 16/105 (15.2%) | 61/480 (12.7%) | 0.487 |
| tested for HIV | 448/451 (99.3%) | 504/508 (99.2%) | 87/89 (97.8%) | 417/419 (99.5) | 0.087 |
| tested positive | 31/448 (6.9%) | 41/504 (8.1%) | 12/87 (13.8%) | 29/417 (7.0%) | 0.034 |
| total HIV positive | 109/526 (20.7%) | 118/581 (20.3%) | 28/103 (27.2%) | 90/478 (18.8%) | |
| Syphilis | n = 529 | n = 586 | n = 106 | n = 480 | |
| tested for syphilis | 23/529 (4.3%) | 572/586 (97.6%) | 102/106 (96.2%) | 470/480 (97.9%) | 0.302 |
| tested positive | 0/23 (0%) | 18/572 (3.1%) | 2/102 (2%) | 16/470 (3.4%) | 0.449 |
| Malaria | n = 562 | n = 105 | n = 457 | ||
| tested for mal | 554/562 (98.6%) | 100/105 (95.2%) | 454/457 (99.3%) | 0.001 | |
| tested positive | 177/554 (31.9%) | 28/100 (28%) | 149/454 (32.8%) | 0.349 | |
| Anaemia (g/dL) | n = 529 | n = 582 | n = 106 | n = 476 | |
| tested for Hb conc. | 147/529 (27.8%) | 569/582 (97.8%) | 101/106 (95.3%) | 468/476 (98.3%) | 0.056 |
| Non-anaemic Hb ≥ 10 g/dL | 89/147 (60.5%) | 346/569 (60.8%) | 60/101 (59.4%) | 286/468 (61.1%) | |
| Mild Hb 8–9.9 g/dL | 46/147 (31.3%) | 166/569 (29.2%) | 29/101 (28.7%) | 137/468 (29.3%) | |
| Moderate Hb 5–7.9 g/dL | 12/147 (8.2%) | 56/569 (9.8%) | 11/101 (10.9%) | 45/468 (9.6%) | |
| Severe Hb <5 g/dL | 0/147 (0%) | 1/569 (0.2%) | 1/101 (1%) | 0/468 (0%) | 0.185 |
| WHO anaemic Hb <11 g/dL | 91/147 (61.9%) | 346/569 (60.8%) | 65/101 (64.4%) | 281/468 (60%) | |
| All | Not interviewed n = 106 | Interviewed n = 480 | P-value | ||
| Age | n = 585 | n = 106 | n = 479 | ||
| <20 | 159 (27.2%) | 30 (28.3%) | 129 (26.9%) | ||
| 20 to <25 | 208 (35.6%) | 40 (37.7%) | 168 (35.1%) | ||
| 25 to <30 | 118 (20.2%) | 18 (17%) | 100 (20.9%) | ||
| 30 to <35 | 64 (10.9%) | 12 (11.3%) | 52 (10.9%) | ||
| 35+ | 36 (6.2%) | 6 (5.7%) | 30 (6.3%) | 0.917 | |
| Gestation in weeks | n = 583 | n = 106 | n = 477 | ||
| median (IQR) | 21.1 (16.9–24.1) | 21.7 (17.6–24.4) | 21.1 (16.9–24.1) | 0.47 | |
| Gravidity | n = 586 | n = 106 | n = 480 | ||
| gravida 1 | 163 (27.9%) | 38 (35.8%) | 125 (26.1%) | ||
| gravida 2 | 134 (22.9%) | 24 (22.6%) | 110 (23%) | ||
| gravida 3 | 114 (19.5%) | 14 (13.2%) | 100 (20.9%) | ||
| gravida 4 | 70 (12%) | 12 (11.3%) | 58 (12.1%) | ||
| gravida 5+ | 105 (17.9%) | 18 (17%) | 87 (18.1%) | 0.22 | |
| Previous miscarriage | n = 586 | n = 106 | n = 480 | ||
| Yes | 21 (3.6%) | 0 (0%) | 21 (4.4%) | 0.028 | |
| Marital status | n = 586 | n = 106 | n = 480 | ||
| married | 466 (79.5%) | 83 (78.3%) | 383 (79.8%) | ||
| widowed | 9 (1.5%) | 2 (1.9%) | 7 (1.5%) | ||
| single | 93 (15.9%) | 15 (14.2%) | 78 (16.3%) | ||
| divorced/separated | 18 (17.2%) | 6 (5.9%) | 12 (12%) | 0.363 | |
WHO Hb: World Health Organization standards for haemoglobin cut-offs for defining anaemia else Kenyan cut-offs
*p-value based on Chi2 for the difference between those interviewed and not interviewed
a: p-value based on Wilcoxon rank-sum for the difference in median between those interviewed and not interviewed
ANC: antenatal care; POCT: point-of-care testing; Hb: haemoglobin concentration
Self-reported treatments for test positives, IPTp for malaria, and haematinic supplementation given at first visit ANC among 480 interviewed women.
| Proportion | Success threshold | Target reached for correct ANC strategies? | |
|---|---|---|---|
| Given CTX | 19/29 (65.5%) | ≥90% | Under-reached |
| Given ARVs | 14/29 (48.3%) | ≥90% | Very under-reached |
| Given 2.4 MU benzathine penicillin or erythromycin | 12/17 (70.6%) | ≥90% | Under-reached |
| Given SP for IPTp among women in 2nd trimester not on CTX | 69/359 (19.2%) | ≥90% | Severely under-reached |
| Given SP for IPTp among women in 1st trimester not on CTX | 5/41 (12.2%) | ||
| Given SP to women also on CTX | 2/80 (2.5%) | ||
| Given 5 mg folic acid with SP | 7/76 (9.2%) | ||
| Given AL, DP or quinine among malaria positives in 2nd trimester | 121/153 (79.1%) | ≥90% | Under-reached |
| Given quinine among malaria positives in 1st trimester | 2/8 (25%) | ≥90% | Severely under-reached |
| Given folic acid | 421/480 (87.7%) | ≥90% | Under-reached |
| - Told to take between 0.4–1.2 mg daily | 378/421 (89.8%) | ||
| - Told to take between 5–10 mg daily | 43/421 (10%) | ||
| Given iron | 434/480 (90.4%) | ≥90% | Reached |
| - Given iron and mentioned side effects | 41/434 (9.4%) | ≥90% | Severely under-reached |
| Normal Hb ≥10 g/dL | n = 286 | ||
| - 60–65 mg elemental iron daily | 193/286 (67.4%) | ≥90% | Under-reached |
| - 120–130 mg elemental iron daily | 4/286 (1.4%) | ||
| - 180–195 mg elemental iron daily | 49/286 (17.1%) | ||
| - Not told dosing | 12/286 (4.2%) | ||
| - Not given any iron | 28/286 (9.8%) | ||
| Mild anaemia Hb 8–9.9 g/dL | n = 137 | ||
| - 60–65 mg elemental iron daily | 86/137 (62.8%) | ||
| - 120–130 mg elemental iron daily | 4/137 (2.9%) | ≥90% | Severely under-reached |
| - 180–195 mg elemental iron daily | 32/137 (23.4%) | ||
| - Not told dosing | 3/137 (2.2%) | ||
| - Not given any iron | 12/137 (8.8%) | ||
| Moderate anaemia Hb 5–7.9 g/dL | n = 45 | ||
| - 60–65 mg elemental iron daily | 20/45 (44.4%) | ||
| - 120–130 mg elemental iron daily | 9/45 (20%) | ≥90% | Severely under-reached |
| - 180–195 mg elemental iron daily | 9/45 (20%) | ||
| - Not told dosing | 2/45 (4.4%) | ||
| - Not given any iron | 5/45 (11.1%) | ||
| No Hb recorded | n = 12 | ||
| - 60–65 mg elemental iron daily | 8/12 (66.7%) | ||
| - 120–130 mg elemental iron daily | 1/12 (8.3%) | ||
| - Not told dosing | 2/12 (16.7%) | ||
| - Not given any iron | 1/12 (8.3%) |
* ≥90% target reached, <90% to ≥60—under-reached, <60% to ≥40 very under-reached, <40% severely under-reached
IPTp: intermittent preventive therapy in pregnancy; ANC: antenatal care; CTX: cotrimoxazole; ARV: antiretroviral; SP:sulfadoxine-pyrimethamine; AL: artemether/lumefantrine; DP: dihydroartemisinin-piperaquine (DP); Hb: haemoglobin concentration
†not on CTX includes women who were tested HIV negative, unknown status, and new positive but were not given CTX same day
‡on CTX includes known HIV positives and new HIV positives who were given CTX same day
Self-reported information given about the tests at first ANC visit among 480 interviewed women.
| Proportion | Success threshold | Target reached for correct ANC strategies? | |
|---|---|---|---|
| Received HIV counselling | 167/480 (34.8%) | ≥90% | Severely under-reached |
| Reported receiving an HIV test among those who had an HIV | 411/417 (98.6%) | ≥90% | Reached |
| test result in ANC register | |||
| Reported told HIV status that | 399/411 (97%) | ≥90% | Reached |
| agree with result in ANC register | |||
| Reported told HIV status that did not | 0/411 (0%) | ||
| agree with result in ANC register | |||
| Reported not told any results for HIVa | 12/411 (2.9%) | ||
| Explained what syphilis is | 83/475 (17.5%) | ≥90% | Severely under-reached |
| Reported receiving a syphilis test among those who had a | 438/470 (93.2%) | ≥90% | Reached |
| syphilis test result in ANC register | |||
| Reported told syphilis status that | 417/438 (95.2%) | ≥90% | Reached |
| agree with result in ANC register | |||
| Reported told syphilis status that did not agree | 2/438 (4.6%) | ||
| with result in ANC register | |||
| Reported not told any results for syphilis | 19/438 (4.3%) | ||
| Advised to inform partners of syphilis positivity | 13/17 (76.5%) | ≥90% | Under-reached |
| Given advice to use mosquito net to prevent malaria | 346/478 (72.4%) | ≥90% | Under-reached |
| Given a mosquito net (n = 349) | 331/349 (94.8%) | ≥90% | Reached |
| Reported receiving a malaria test among those who had a | 445/454 (98%) | ≥90% | Reached |
| malaria result in ANC register | |||
| Reported told malaria status that | 420/445 (94.4%) | ≥90% | Reached |
| agree with result in ANC register | |||
| Reported told malaria status that did not agree | 11/445 (2.5%) | ||
| with result in ANC register | |||
| Reported not told any results for malaria | 14/445 (3.1%) | ||
| Given advice to eat food with iron | 132/480 (27.5%) | ≥90% | Severely under-reached |
| Explained what anaemia is | 107/480 (22.3%) | ≥90% | Severely under-reached |
| Reported receiving an anaemia test among those who had an | 448/468 (95.7%) | ≥90% | Reached |
| Hb result in ANC register | |||
| Reported told an anaemia status that | 235/448 (52.5%) | ≥90% | Very under-reached |
| agree with Hb level in ANC register | |||
| Reported told an anaemia status that | 60/448 (13.4%) | ||
| did not agree with Hb level in ANC register | |||
| Reported not told any results for anaemia test | 153/448 (34.2%) |
* ≥90% target reached, <90% to ≥60 under-reached, <60% to ≥40 very under-reached, <40% severely under-reached
ANC: antenatal care; Hb: haemoglobin concentration; KP: known HIV positives
a: Women reported not told results for HIV, syphilis or malaria were all negative based on ANC registers
Predictors of pregnant women not having a full antenatal screening profile at first visits (n = 728).
| Univariate analysis | Multivariate model | |||||
|---|---|---|---|---|---|---|
| n = 728 | Women without full profile in ANC register | RR (95% CI) of not having a full profile in ANC register | p-value | RR | p-value | |
| | 0.003 | |||||
| 143 (19.6%) | 6 (4.2%) | Reference | Reference | |||
| 398 (54.7%) | 46 (11.6%) | 2.7 (1.5–4.8) | 2.9 (1.7–4.9) | <0.0001 | ||
| 187 (25.7%) | 18 (9.6%) | 2.1 (1.2–3.7) | 2.9 (1.6–5.1) | <0.0001 | ||
| | 0.01 | |||||
| 116 (16.0%) | 6 (5.2%) | Reference | Reference | |||
| 579 (79.6%) | 59 (10.2%) | 2.4 (1.2–5.0) | 2.6 (1.5–4.7) | 0.001 | ||
| 32 (4.4%) | 5 (15.6%) | 3.7 (1.5–9.1) | 4.1 (1.7–9.6) | 0.001 | ||
| | 0.89 | |||||
| 194 (26.7%) | 19 (9.8%) | Reference | ||||
| 157 (21.6%) | 17 (10.8%) | 1.1 (0.5–2.4) | ||||
| 377 (51.8%) | 34 (9.0%) | 0.9 (0.7–1.3) | ||||
| | 0.52 | |||||
| 701 (96.3%) | 68 (9.7%) | Reference | ||||
| 27 (3.7%) | 2 (7.4%) | 0.6 (0.1–2.9) | ||||
| | 0.35 | |||||
| 587 (80.6%) | 54 (9.2%) | Reference | ||||
| 141 (19.4%) | 16 (11.3%) | 1.2 (0.8–1.9) | ||||
| | 0.0006 | |||||
| 446 (61.3%) | 27 (6.1%) | Reference | Reference | |||
| 151 (20.7%) | 20 (13.3%) | 2.2 (0.8–6.1) | 1.9 (0.6–5.6) | 0.253 | ||
| 131 (18.0%) | 23 (17.6%) | 2.9 (1.7–5.0) | 3.0 (1.8–5.1) | <0.0001 | ||
| | 0.4 | |||||
| 151 (20.7%) | 20 (13.2%) | Reference | ||||
| 297 (40.8%) | 19 (6.4%) | 0.5 (0.2–1.6) | ||||
| 280 (38.5%) | 31 (11.1%) | 0.9 (0.3–2.9) | ||||
| | 0.8 | |||||
| | 206 (28.3%) | 16 (7.8%) | Reference | |||
| 167 (22.9%) | 19 (11.4%) | 1.5 (0.4–5.5) | ||||
| 355 (48.8%) | 35 (9.9%) | 1.2 (0.4–3.3) | ||||
| | <0.0001 | |||||
| 91 (12.5%) | 3 (3.3%) | Reference | Reference | |||
| 637 (87.5%) | 67 (10.5%) | 3.3 (2.0–5.5) | 2.1 (1.2–3.7) | 0.01 | ||
*Wald test
**n = 727
a: Staff turnover was categorized into low, medium and high defined as having 2, 1, and 0 skilled healthcare workers who received training at the start of the programme and remained for all 8 months of implementation respectively
b: Facility volume was split into low, medium, and high for <30, 30–40, and 50–70 monthly ANC visits respectively
c: Skilled staff was defined as the total number of nurses, clinical officers, and HIV testing counsellors the facility had
ANC: antenatal care; RR: relative risk
Fig 2Proficiency scores (%) of healthcare worker checklists in point-of-care testing.
The boxes represent interquartile ranges (25% to 75% percentile); the solid line in the box is the median (50th percentile); The lower and upper whiskers represent the minimum and maximum values, excluding outlier; the dots represent outliers, defined as values less than 1.5 times the lower quartile.